Panzyga

BIOLOGICAL5 trials

Sponsors

Octapharma

Conditions

Chronic Immune ThrombocytopeniaChronic Lymphocytic LeukemiaHypogammaglobulinemiaPediatric Acute-Onset Neuropsychiatric SyndromePediatric Chronic Inflammatory Demyelinating PolyneuropathyPrimary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG

Phase 3

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

CompletedNCT04502030

OctapharmaChronic Lymphocytic Leukemia, Hypogammaglobulinemia

Start: 2020-10-05End: 2025-09-19Updated: 2026-06-04

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

CompletedNCT04508530

OctapharmaPediatric Acute-Onset Neuropsychiatric Syndrome

Start: 2021-06-30End: 2024-10-30Updated: 2026-01-07

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

RecruitingNCT04929236

OctapharmaPediatric Chronic Inflammatory Demyelinating Polyneuropathy

Start: 2023-10-01End: 2028-12-31Target: 30Updated: 2026-08-05

Phase 4

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

TerminatedNCT03866798

OctapharmaChronic Immune Thrombocytopenia

Start: 2020-01-21End: 2024-05-17Updated: 2024-09-24

Unknown Phase

Non-Interventional Study on the Tolerability and Efficacy of IVIG

CompletedNCT02303093

OctapharmaPrimary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG

Start: 2011-08-01End: 2020-06-05Updated: 2021-06-29